Taigen Biopharmaceuticals Holdings Ltd (4157) — Capital Reinvestment Ratio
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Capital Reinvestment Ratio of 0.01x as of March 2025, meaning it reinvests 0% of its operating cash flow (NT$67.16 Million) in capital expenditures (NT$874.00K). See 4157 equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Taigen Biopharmaceuticals Holdings Ltd Capital Reinvestment Ratio (2021–2023)
This chart tracks Taigen Biopharmaceuticals Holdings Ltd's Capital Reinvestment Ratio across 2 annual periods. Check Taigen Biopharmaceuticals Holdings Ltd (4157) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Taigen Biopharmaceuticals Holdings Ltd (2021–2023)
Year-by-year Capital Reinvestment Ratio for Taigen Biopharmaceuticals Holdings Ltd from 2021 to 2023. For live market cap and broader valuation context, see market value of Taigen Biopharmaceuticals Holdings Ltd.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.36x | NT$20.74 Million | NT$7.39 Million | ▲ +1795.4% |
| 2021 | 0.02x | NT$629.07 Million | NT$11.83 Million | — |